Overview

Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Status:
Withdrawn
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
Phase:
Phase 3
Details
Lead Sponsor:
Paratek Pharmaceuticals Inc
Treatments:
Linezolid